CL2015002603A1 - Anticuerpos humanos contragrem1. - Google Patents
Anticuerpos humanos contragrem1.Info
- Publication number
- CL2015002603A1 CL2015002603A1 CL2015002603A CL2015002603A CL2015002603A1 CL 2015002603 A1 CL2015002603 A1 CL 2015002603A1 CL 2015002603 A CL2015002603 A CL 2015002603A CL 2015002603 A CL2015002603 A CL 2015002603A CL 2015002603 A1 CL2015002603 A1 CL 2015002603A1
- Authority
- CL
- Chile
- Prior art keywords
- grem1
- antibodies
- human antibodies
- treat
- modes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782874P | 2013-03-14 | 2013-03-14 | |
| US201361883218P | 2013-09-27 | 2013-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002603A1 true CL2015002603A1 (es) | 2016-03-04 |
Family
ID=50390267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002603A CL2015002603A1 (es) | 2013-03-14 | 2015-09-11 | Anticuerpos humanos contragrem1. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10377817B2 (enExample) |
| EP (1) | EP2970448B1 (enExample) |
| JP (2) | JP6581075B2 (enExample) |
| KR (1) | KR20150129718A (enExample) |
| CN (1) | CN105189548A (enExample) |
| AU (1) | AU2014241442B2 (enExample) |
| BR (1) | BR112015021979A2 (enExample) |
| CA (1) | CA2904644C (enExample) |
| CL (1) | CL2015002603A1 (enExample) |
| EA (1) | EA201591762A1 (enExample) |
| ES (1) | ES2898620T3 (enExample) |
| HK (1) | HK1220469A1 (enExample) |
| IL (1) | IL240769A0 (enExample) |
| MX (1) | MX369574B (enExample) |
| PH (1) | PH12015501865A1 (enExample) |
| SG (2) | SG10201707518YA (enExample) |
| WO (1) | WO2014159010A1 (enExample) |
| ZA (1) | ZA201506113B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104321342B (zh) * | 2012-03-15 | 2017-12-22 | 首尔大学校产学协力团 | Gremlin‑1抗体 |
| SG10201707518YA (en) | 2013-03-14 | 2017-10-30 | Regeneron Pharma | Human antibodies to grem 1 |
| JP7038064B2 (ja) | 2016-04-18 | 2022-03-17 | セルデックス セラピューティクス インコーポレイテッド | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
| WO2017218515A1 (en) * | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| CN106399316B (zh) * | 2016-08-26 | 2019-03-01 | 西安交通大学第一附属医院 | 用于识别Gremlin-1的核酸适配子及其应用 |
| CN109641954A (zh) * | 2016-08-29 | 2019-04-16 | 里珍纳龙药品有限公司 | 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 |
| JP7350313B2 (ja) | 2016-12-16 | 2023-09-26 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 |
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| MA49273A (fr) | 2017-03-22 | 2020-02-05 | Bluefin Biomedicine Inc | Anticorps anti-tmeff1 et conjugués anticorps-médicament |
| WO2018175924A1 (en) * | 2017-03-24 | 2018-09-27 | The Broad Institute, Inc. | Methods and compositions for regulating innate lymphoid cell inflammatory responses |
| GB201802486D0 (en) * | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| SG11202012312UA (en) * | 2018-06-18 | 2021-01-28 | UCB Biopharma SRL | Gremlin-1 antagonist for the prevention and treatment of cancer |
| WO2020106461A2 (en) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
| WO2021102173A1 (en) * | 2019-11-21 | 2021-05-27 | Unity Biotechnology | Antibodies directed to tie-2 and methods of use |
| AU2021366287A1 (en) * | 2020-10-20 | 2023-04-13 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof |
| TW202237642A (zh) * | 2021-01-08 | 2022-10-01 | 美商１０Ｘ基因組學有限公司 | 對冠狀病毒具有特異性的抗原結合多肽及其用途 |
| WO2022152290A1 (en) * | 2021-01-18 | 2022-07-21 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
| US20240190950A1 (en) * | 2021-03-11 | 2024-06-13 | Shanghai Jiao Tong University | Method of treating diseases using gremlin1 antagonists |
| GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| US20250257123A1 (en) * | 2022-04-20 | 2025-08-14 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
| TW202409078A (zh) * | 2022-07-18 | 2024-03-01 | 中國大陸商蘇州創勝醫藥集團有限公司 | 穩定之包含抗gremlin1抗體的藥物製劑 |
| CN115786495A (zh) * | 2022-10-24 | 2023-03-14 | 杭州市第七人民医院 | 检测基因表达量的试剂在制备尼古丁加重的糖尿病肾病的筛查试剂盒中的用途 |
| EP4694930A1 (en) * | 2023-04-13 | 2026-02-18 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving grem1 antagonists for treatment of cancer |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| AU6267098A (en) | 1997-02-05 | 1998-08-25 | Regents Of The University Of California, The | Morphogenic proteins |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2463143A1 (en) | 2001-10-31 | 2003-07-10 | Alcon, Inc. | Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma |
| EP1738767A1 (en) | 2001-10-31 | 2007-01-03 | Alcon, Inc. | Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| JP2008531525A (ja) | 2005-02-24 | 2008-08-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチド製剤を安定化する化合物 |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| US8258256B2 (en) | 2006-01-05 | 2012-09-04 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US7420041B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2007124486A2 (en) | 2006-04-21 | 2007-11-01 | Childrens Hospital Los Angeles | Bmp4 inhibitors |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US8383349B2 (en) * | 2007-03-16 | 2013-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bone morphogenetic protein antagonist and uses thereof |
| SI2644192T1 (sl) | 2007-09-28 | 2017-08-31 | Pfizer Inc. | Ciljanje rakavih celic z uporabo nanodelcev |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| CN104321342B (zh) | 2012-03-15 | 2017-12-22 | 首尔大学校产学协力团 | Gremlin‑1抗体 |
| SG10201707518YA (en) | 2013-03-14 | 2017-10-30 | Regeneron Pharma | Human antibodies to grem 1 |
-
2014
- 2014-03-07 SG SG10201707518YA patent/SG10201707518YA/en unknown
- 2014-03-07 CN CN201480014151.0A patent/CN105189548A/zh active Pending
- 2014-03-07 US US14/775,637 patent/US10377817B2/en active Active
- 2014-03-07 EP EP14713709.5A patent/EP2970448B1/en active Active
- 2014-03-07 SG SG11201506459PA patent/SG11201506459PA/en unknown
- 2014-03-07 MX MX2015011616A patent/MX369574B/es active IP Right Grant
- 2014-03-07 JP JP2016500767A patent/JP6581075B2/ja active Active
- 2014-03-07 EA EA201591762A patent/EA201591762A1/ru unknown
- 2014-03-07 KR KR1020157024673A patent/KR20150129718A/ko not_active Withdrawn
- 2014-03-07 AU AU2014241442A patent/AU2014241442B2/en active Active
- 2014-03-07 ES ES14713709T patent/ES2898620T3/es active Active
- 2014-03-07 WO PCT/US2014/021471 patent/WO2014159010A1/en not_active Ceased
- 2014-03-07 CA CA2904644A patent/CA2904644C/en active Active
- 2014-03-07 HK HK16108451.7A patent/HK1220469A1/zh unknown
- 2014-03-07 BR BR112015021979A patent/BR112015021979A2/pt not_active Application Discontinuation
-
2015
- 2015-08-21 ZA ZA2015/06113A patent/ZA201506113B/en unknown
- 2015-08-23 IL IL240769A patent/IL240769A0/en unknown
- 2015-08-25 PH PH12015501865A patent/PH12015501865A1/en unknown
- 2015-09-11 CL CL2015002603A patent/CL2015002603A1/es unknown
-
2019
- 2019-05-08 JP JP2019087970A patent/JP2019151654A/ja active Pending
- 2019-06-27 US US16/454,663 patent/US11634480B2/en active Active
-
2023
- 2023-03-06 US US18/117,883 patent/US20230192831A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6581075B2 (ja) | 2019-09-25 |
| PH12015501865A1 (en) | 2015-12-07 |
| US11634480B2 (en) | 2023-04-25 |
| SG11201506459PA (en) | 2015-09-29 |
| JP2019151654A (ja) | 2019-09-12 |
| KR20150129718A (ko) | 2015-11-20 |
| US10377817B2 (en) | 2019-08-13 |
| CA2904644C (en) | 2022-09-20 |
| US20230192831A1 (en) | 2023-06-22 |
| EP2970448B1 (en) | 2021-11-03 |
| US20160024195A1 (en) | 2016-01-28 |
| WO2014159010A1 (en) | 2014-10-02 |
| MX369574B (es) | 2019-11-13 |
| AU2014241442A1 (en) | 2015-10-15 |
| EP2970448A1 (en) | 2016-01-20 |
| ZA201506113B (en) | 2016-07-27 |
| JP2016519650A (ja) | 2016-07-07 |
| ES2898620T3 (es) | 2022-03-08 |
| AU2014241442B2 (en) | 2018-11-15 |
| IL240769A0 (en) | 2015-10-29 |
| US20200157194A1 (en) | 2020-05-21 |
| MX2015011616A (es) | 2015-12-17 |
| BR112015021979A2 (pt) | 2017-08-29 |
| HK1220469A1 (zh) | 2017-05-05 |
| CN105189548A (zh) | 2015-12-23 |
| EA201591762A1 (ru) | 2015-12-30 |
| SG10201707518YA (en) | 2017-10-30 |
| CA2904644A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| CO2017002170A2 (es) | Terapia de combinación para tratar un paramixovirus | |
| UY36032A (es) | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| PL3303632T3 (pl) | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze | |
| MX2016004441A (es) | Tratamiento del cancer con una combinacion de plinabulina y taxano. | |
| CL2017000888A1 (es) | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas | |
| CL2017001736A1 (es) | Anticuerpos anti-cd47 y uso de los mismos. | |
| UY35967A (es) | Moléculas de anticuerpo que se unen a pd-1 y usos de las mismas | |
| CL2018000429A1 (es) | Moduladores de la expresión de kras | |
| CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
| CL2017001943A1 (es) | Terapias de combinación para el tratamiento de cánceres | |
| UY36862A (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
| UY35973A (es) | Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas | |
| MX379193B (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| MX392779B (es) | Anticuerpos anti-cd27 | |
| MX2017012380A (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| GT201600050A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso | |
| PH12015501865A1 (en) | Human antibodies to grem 1 | |
| BR112017008799A2 (pt) | composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal | |
| MX2018006613A (es) | Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos. | |
| NI201500175A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| MX2017004196A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| MX372759B (es) | Composiciones para usarse en mejorar la función renal. | |
| PH12016501838A1 (en) | Compounds and their methods of use |